miR-34b inhibits nasopharyngeal carcinoma cell proliferation by targeting ubiquitin-specific peptidase 22
Authors Xiao J, Li Y, Zhang W, Jiang Y, Du B, Tan Y
Received 15 October 2015
Accepted for publication 28 January 2016
Published 16 March 2016 Volume 2016:9 Pages 1525—1534
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Chang Liu
Peer reviewer comments 2
Editor who approved publication: Dr Faris Farassati
Jianyong Xiao,1 Yingying Li,2 Wenyin Zhang,1 Yanni Jiang,1 Biaoyan Du,3 Yuhui Tan1
1Department of Biochemistry, Guangzhou University of Chinese Medicine, 2Department of Internal Medicine, Guangzhou Eighth People’s Hospital, 3Department of Pathology, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of China
Objectives: This study aimed to investigate the precise role of miR-34b in nasopharyngeal carcinoma (NPC).
Materials and methods: The expression of miR-34b and transcription of ubiquitin-specific peptidase 22 (USP22) were examined using quantitative reverse transcription-polymerase chain reaction. Western blot analysis was used to measure the protein expression of USP22. A dual-luciferase assay was used to investigate the interaction between miR-34b and USP22. Cell viability was determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. The cell cycle was analyzed by propidium iodide staining followed by flow cytometry analysis.
Results: miR-34b was significantly downregulated in NPC tissues and NPC cell lines. Overexpression of miR-34b in NPC SUNE-6-10B cells inhibited cell viability and proliferation. USP22 was highly expressed in NPC cells and promoted cell viability and proliferation. Restoration of USP22 expression could reverse the effect of miR-34b on NPC cell viability and proliferation.
Conclusion: miR-34b acts as a tumor suppressor in NPC, which is mediated via repression of the oncogene USP22.
Keywords: cell proliferation, miR-34b, nasopharyngeal carcinoma, overexpression, USP22
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]